Papillary Renal Cell Carcinoma - 26 Studies Found Recruiting : Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma : Papillary Renal Cell Carcinoma : 2015-06-19 : Drug: axitinib Other Name: Inlyta Recruiting : Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma : Renal Cell Carcinoma Hereditary Leiomyomatosis and Renal Cell Cancer Drug: Vandetanib Vandetanib is Recruiting : A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer : Papillary Renal Cell Carcinoma : 2013-12-20 : Drug: INC280 Supplied by Novartis as film-coated tablet for oral use. Completed : A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) : Carcinoma, Renal Cell : 2008-07-29 : Drug: foretinib (formerly GSK1363089 or XL880) treatment with oral foretinib on one of 2 dosing regimens Active, not recruiting : A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) : Papillary Renal Cell Cancer : 2014-04-23 : Drug: AZD6094 AZD6094 is a potent and selective small molecule cMet kinase inhibitor. Active, not recruiting : Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery : Recurrent Renal Cell Carcinoma Stage III Renal Cell Cancer : 2012-09-14 : Drug: Erlotinib Hydrochloride Completed : Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T : Prostate Cancer : 2010-08-01 : Biological: Cancer Macrobead placement in abdominal cavity 8 macrobeads per kilogram Terminated : Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer : Kidney Cancer : 2008-01-22 : Biological: bevacizumab 15 mg/kg over 90 minutes every 3 weeks Terminated : Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer : Kidney Cancer : 2007-10-05 : Drug: sunitinib malate Completed : Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer : Kidney Cancer : 2007-04-11 : Drug: sunitinib malate Next >>>